Brain – Start
The Brain Start stack pairs three widely studied neuropeptides — Semax, Selank and P21 — into one curated kit for cognitive and neuroplasticity research. It supports work on attention, stress modulation and BDNF-linked signalling.
Each peptide is supplied at research-grade purity for laboratory use. For research purposes only; not for human consumption.
Il prezzo originale era: 209,00 €.178,00 €Il prezzo attuale è: 178,00 €.
Un kit di ricerca nootropica che combina Semax, Selank e P21 per studi su cognizione, concentrazione e neuroplasticità.
Temporaneamente non disponibile. Lascia i tuoi dati e ti avviseremo appena torna.
Brain - Start - Foundational Cognitive Research Stack
Explored with Semax
Investigated with Semax
Studied with Selank
Focus of P21 (P021) research
Explored with P21 (P021)
Potential with Selank
Research with Semax
Key area for Selank
Description
Mechanism of Action
Semax, a synthetic peptide, is researched for its neuroprotective and nootropic properties, potentially modulating BDNF and neurotransmitter activity. Selank, an anxiolytic peptide, is studied for its impact on stress response and immune function, complementing cognitive research. P21 (P021), a neurotrophic factor mimic, is explored for promoting neurogenesis, synaptic plasticity, and neuronal survival, offering a multi-faceted approach to brain health research.
Benefits
- Cognitive Enhancement – Investigated with Semax for focus and memory.
- Stress Modulation – Explored with Selank for anxiolytic effects.
- Neuroprotection Research – Supported by Semax and P21’s potential.
- Synaptic Plasticity – A key area of study for P21 (P021).
- Mood Regulation – Potential research focus with Selank.
- Neuronal Growth – P21 (P021) is studied for its role in neurogenesis.
Research Data
Semax
| Study / Model | Reported effect |
|---|---|
| Ischemic stroke patients (clinical study) | Improved neurological recovery and reduced infarct progression when administered within acute window |
| Rat middle cerebral artery occlusion model | ↓ Infarct volume; ↑ neuronal survival in penumbra region |
| Rat hippocampal tissue assay | ↑ BDNF and NGF expression within hours of administration |
| Healthy human cognitive trials | ↑ Attention, memory consolidation, and operator performance under fatigue |
| Chronic stress rodent model | Reduced anxiety-related behaviors; normalized HPA-axis activity |
| In vitro neuronal culture | Enhanced dopaminergic and serotonergic signaling; protection against oxidative injury |
| Optic nerve atrophy model | ↑ Retinal ganglion cell survival and improved visual response markers |
Selank
| Study / Model | Reported effect |
|---|---|
| Generalized anxiety disorder clinical trials | ↓ anxiety scores comparable to medazepam without sedation or withdrawal |
| Rat elevated plus-maze model | ↓ anxiety-like behavior; ↑ open-arm exploration time |
| Cortical neurotransmitter analysis (rodent) | Normalized GABA turnover; ↑ serotonin and dopamine metabolism |
| BDNF expression studies in hippocampus | ↑ BDNF mRNA expression supporting neuroplasticity |
| Stress-induced immunosuppression models | Restored interferon and cytokine balance; ↑ immune resilience |
| Cognitive performance tasks in healthy volunteers | ↑ attention, memory consolidation, and mental endurance |
| Enkephalin degradation assays | Inhibition of enkephalin breakdown; prolonged endogenous opioid activity |
P21 (P021)
| Study / Model | Reported effect |
|---|---|
| Aged rat hippocampus | ↑ BDNF expression, ↑ neurogenesis, improved spatial memory performance |
| 3xTg-AD Alzheimer’s mouse model | ↓ tau hyperphosphorylation, ↓ amyloid-β pathology, preserved cognitive function |
| Down syndrome mouse model (Ts65Dn) | Restored dentate gyrus neurogenesis and rescued learning deficits |
| Streptozotocin-induced cognitive impairment (rats) | ↑ synaptic plasticity markers, ↓ neuroinflammation, improved memory retention |
| In vitro neuronal cultures | ↑ CREB phosphorylation and BDNF/TrkB signaling activity |
| Traumatic brain injury rodent model | ↓ neuronal loss, ↑ dendritic spine density in hippocampal regions |
Stack Suggestions
This research bundle is designed for investigators exploring foundational cognitive support, stress response modulation, and neurotrophic pathways. It offers a synergistic approach to understanding brain health and resilience in research models.
Pen Dosage Chart
Semax
| Semax Pen 30 mg | |
|---|---|
| Volume | 3.0 mL (after reconstitution) |
| mg/mL | 10 mg/mL |
| Click-to-Dose | 1 click = 0.1 mg |
| Example(s) | 3 clicks = 0.3 mg; 6 clicks = 0.6 mg |
Selank
| Selank Pen 10 mg | |
|---|---|
| Volume | 2.0 mL (after reconstitution) |
| mg/mL | 5.0 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 30 clicks = 1.5 mg; 60 clicks = 3 mg |
P21 (P021)
| P21 Pen 10 mg | |
| Volume | 2 mL |
| mg/mL | 5 mg/mL |
| Click-to-Dose | 1 click = 0.05 mg |
| Example(s) | 10 clicks = 0.5 mg |
Dosage & Protocols Variations
Semax
Standard Research Protocol
- Dose: 0.3 – 0.6 mg (= 3–6 clicks)
- Duration: 2 – 4 weeks
- Frequency: Daily
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Baseline cognitive and neurotrophic research applications.
Therapeutic Research Protocol
- Dose: 0.6 – 1.2 mg (= 6–12 clicks)
- Duration: 1 – 2 weeks
- Frequency: Daily, divided into 2 – 3 doses
- Cycle Interval: 3 – 4 weeks off before repeating
- Goal / Description: Higher-dose protocol used in stroke recovery and neuroprotection models.
Biohacker Protocol (experimental)
- Dose: 0.1 – 0.3 mg (= 1–3 clicks)
- Duration: 4 – 6 weeks
- Frequency: Daily, morning administration
- Cycle Interval: 2 weeks off before repeating
- Goal / Description: Low-dose continuous exposure for cognitive and focus research.
Selank
Standard Research Protocol
- Dose: 0.25 – 0.5 mg (= 5–10 clicks)
- Duration: 2 – 3 weeks
- Frequency: Daily (SubQ)
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Baseline protocol for anxiolytic and cognitive stability models.
Therapeutic Research Protocol
- Dose: 0.5 – 0.9 mg (= 10–18 clicks)
- Duration: 3 – 4 weeks
- Frequency: 2× daily, divided doses
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Higher-dose protocol used in stress-response and GABAergic modulation studies.
Biohacker Protocol (experimental)
- Dose: 0.1 – 0.2 mg (= 2–4 clicks)
- Duration: 4 – 6 weeks
- Frequency: Daily microdose
- Cycle Interval: 2 weeks off before repeating
- Goal / Description: Low-dose continuous exposure for cognitive and mood-balance research.
Stacked Protocol (Selank + Semax)
- Dose: 0.3 mg Selank + 0.3 mg Semax (= 6 clicks)
- Duration: 2 – 3 weeks
- Frequency: Daily
- Cycle Interval: 3 – 4 weeks off before repeating
- Goal / Description: Combined neuropeptide protocol for cognitive and anxiolytic research models.
P21 (P021)
Standard Research Protocol
- Dose: 0.5 – 1.0 mg
- Duration: 4 – 8 weeks
- Frequency: Daily, oral or intranasal
- Cycle Interval: 2 – 4 weeks off before repeating
- Goal / Description: Baseline cognitive and neurotrophic research applications.
Neuroprotective Research Protocol
- Dose: 1.0 – 2.0 mg
- Duration: 8 – 12 weeks
- Frequency: Daily
- Cycle Interval: 4 weeks off before repeating
- Goal / Description: Extended-duration models targeting BDNF upregulation and neurogenesis.
Biohacker Protocol (experimental)
- Dose: 0.25 – 0.5 mg
- Duration: Continuous
- Frequency: 5 days on, 2 days off
- Cycle Interval: Continuous with weekly pause
- Goal / Description: Low-dose continuous exposure for long-term cognitive research models.
Possible Side Effects
Semax
Semax is generally well-tolerated in clinical and preclinical research, including intranasal and subcutaneous administration studies.
Reported side effects are infrequent and typically mild:
- Mild nasal irritation or transient burning sensation with intranasal use.
- Headache or lightheadedness during initial dosing.
- Temporary changes in alertness or sleep patterns.
- Mild fatigue or restlessness in sensitive subjects.
- Localized redness at subcutaneous injection sites.
No evidence of hormonal, cardiovascular, or systemic adverse effects has been observed in available research data. Long-term safety beyond standard study durations remains under investigation in experimental models.
Selank
Selank is generally well-tolerated in animal and limited human clinical studies, with no significant adverse effects reported at standard research doses.
Reported observations include:
- Mild transient drowsiness or fatigue during initial dosing.
- Occasional headache or lightheadedness in sensitive subjects.
- Localized irritation or redness at the injection site.
- Rare reports of mild nasal discomfort with intranasal administration.
Unlike classical anxiolytics, Selank has not been observed to produce sedation, dependence, withdrawal, or cognitive impairment in available research data. No evidence of hormonal, hepatic, or cardiovascular adverse effects has been documented.
P21 (P021)
P21 is generally well-tolerated in preclinical and animal studies.
Reported side effects are rare and mild:
- Mild transient fatigue or drowsiness during initial dosing periods.
- Localized irritation or redness at injection site.
- Occasional headache or lightheadedness reported in sensitive subjects.
- Subtle mood fluctuations during early adaptation phase.
No evidence of neurotoxic, hepatic, or systemic adverse effects has been observed in available research data.
Product Attributes
Scientific References
Semax
- Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus Animal | In vitro
- Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats Animal
- Heptapeptide Semax Effects on Expression of Genes Related to Neurotransmitter Systems Animal | In vitro
- Heptapeptide semax attenuates the effects of chronic unpredictable stress in rats Animal
- The nootropic and analgesic effects of Semax following different routes of administration Animal
- Effect of Semax and its C-terminal fragment PGP on the in vivo dopamine release in the nucleus accumbens of rats Animal
- Semax, an analog of ACTH(4-7), regulates expression of immune response genes in ischemic rat brain Animal
- Semax: research overview, mechanisms, and effects Observational | Animal
Selank
- Anxiolytic activity of the heptapeptide Selank in clinical trials Human RCT | Observational
- Effects of Selank on the expression of genes encoding inflammatory factors and BDNF Animal | In vitro
- Selank enhances the expression of BDNF and the trkB receptor in the hippocampus Animal
- Comparative study of the anxiolytic effects of Selank and medazepam in patients with generalized anxiety disorder Human RCT
- Effect of Selank on monoamine neurotransmitter metabolism in the brain of rats Animal
- Selank and its analogs modulate GABAergic transmission in experimental anxiety models Animal | In vitro
- Peptide Selank as a candidate for the correction of cognitive deficits Animal
- Immunomodulatory and anxiolytic properties of the synthetic peptide Selank Observational | Animal
P21 (P021)
- Neurogenic and neurotrophic effects of BDNF peptides in mouse hippocampal primary neuronal cell cultures Animal | In vitro
- A small molecule peptide inhibitor of amyloid plaque, oxidative stress, and neuronal loss Animal | In vitro
- Ciliary neurotrophic factor derived peptide P021 ameliorates plaque pathology and improves cognition in Alzheimer disease mouse model Animal
- Neurotrophic peptide P021 rescues hippocampal neurogenesis and synaptic plasticity in a tauopathy mouse model Animal | In vitro
- P021 rescues tau pathology and behavioral deficits in a mouse model of tauopathy by inhibiting GSK-3β Animal
- Neurotrophic compound P021 reduces neuroinflammation and enhances cognitive function in aged rats Animal
- Peptidomimetic P021 promotes neurogenesis and reduces glycogen synthase kinase-3 activity in Down syndrome models Animal | In vitro
- CNTF-derived peptide rescues synaptic and cognitive deficits in a 3xTg-AD model Animal
Contenuto della confezione
Ogni prodotto arriva in una confezione PEPTIDE.Power premium dal design esclusivo, progettata per praticità, igiene e conservazione sicura nel frigorifero. All’interno troverai tutto il necessario per il tuo protocollo di ricerca completo:
- 1× penna per iniezione monouso pre-miscelata
- Alimentata dalla nostra esclusiva PSM Technology™ – sistema di stabilizzazione e miscelazione di precisione per una potenza costante
- 10× aghi ultrasottili (33G, 4 mm)
- 10× tamponi imbevuti di alcol per una preparazione sterile
- Inserto interno in schiuma stabilizzante per evitare scossoni durante il trasporto
- Pannello di istruzioni stampato all’interno della confezione per una rapida consultazione
- Sigillo di sicurezza che garantisce che la confezione non sia stata aperta o manomessa
Conservazione
Conserva il prodotto in frigorifero a 1 – 8°C immediatamente dopo la consegna. Per mantenere una stabilità ottimale, tieni la penna al riparo dalla luce e non esporla a ripetuti sbalzi di temperatura.
Una volta ricostituiti (tutte le nostre penne sono pre-miscelate), i composti per la ricerca rimangono stabili per 6 – 8 settimane con una corretta refrigerazione.
Non congelare dopo la ricostituzione. Tieni sempre la confezione chiusa affinché penna, aghi e tamponi imbevuti di alcol restino puliti e protetti.
Per risultati ottimali, utilizza il prodotto con costanza entro il periodo consigliato e segui sempre il tuo protocollo di ricerca.
Consegna
Spediamo con consegna il giorno successivo nell’UE tramite DHL Express o UPS Express.
Tutti gli ordini vengono preparati freschi il giorno della spedizione, collocati in scatole di trasporto EPS a catena del freddo e spediti con elementi refrigeranti per mantenere una temperatura stabile durante tutto il tragitto.
Il nostro processo logistico è progettato affinché il pacco arrivi entro la notte, evitando ritardi doganali all’interno dell’Unione Europea.
I prodotti vengono spediti dalla nostra struttura nell’UE, garantendo nessun dazio di importazione, nessuno sdoganamento e sempre una consegna rapida e sicura.
Pagamento
A causa della natura dei peptidi per la ricerca e della categoria ad alto rischio assegnata dai gestori dei pagamenti, le società emittenti di carte di credito generalmente non supportano i commercianti di questo settore.
Per questo motivo accettiamo principalmente bonifici bancari.
Collaboriamo inoltre con un fornitore di pagamenti in criptovaluta e, di tanto in tanto, il pagamento con carta può essere disponibile a seconda della disponibilità del gestore.
All’interno dell’Unione Europea, i bonifici SEPA sono veloci, economici e di solito arrivano entro pochi minuti o poche ore, rendendo il processo di pagamento semplice e immediato.
Una volta ricevuto il bonifico, il tuo ordine viene preparato immediatamente e spedito lo stesso giorno, in base all’orario limite giornaliero.
Ti preghiamo di notare che non effettuiamo spedizioni il venerdì né nei giorni precedenti le festività ufficiali. Questo serve a garantire che i pacchi possano essere consegnati il giorno lavorativo successivo e non restino in transito durante i fine settimana o le festività.
Questo metodo garantisce conformità, sicurezza e continuità del servizio per tutti i clienti nell’UE.
Non hai trovato la risposta alla tua domanda?
Vedi tutte le domande frequentiRELATED PRODUCTS
